A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel with Gemcitabine to Determine the Safety and Pharmacokinetics in Subjects with Advanced Solid Malignancies (Sanofi-Aventis TCD11068).

Trial Profile

A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel with Gemcitabine to Determine the Safety and Pharmacokinetics in Subjects with Advanced Solid Malignancies (Sanofi-Aventis TCD11068).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2013

At a glance

  • Drugs Cabazitaxel; Gemcitabine; Midazolam
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jan 2012 Actual patients number is 22 as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date changed from 1 Jun 2013 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top